Resistell
Private Company
Funding information not available
Overview
Resistell is an EPFL spin-off and private diagnostics company based in Basel, Switzerland, focused on addressing the global crisis of antimicrobial resistance. Its core innovation is a nanomotion-based platform that detects bacterial metabolic activity to determine antibiotic susceptibility within one hour, a significant improvement over standard culture-based methods that take 24-48 hours. The company has validated its technology through peer-reviewed publication in Nature Communications, initiated international clinical studies, and formed strategic partnerships with hospitals and foundations. Resistell is positioned in the high-growth AST market, aiming to reduce inappropriate antibiotic use, lower healthcare costs, and save lives.
Technology Platform
Proprietary nanomotion technology that detects bacterial metabolic activity via nanoscale vibrations to perform phenotypic antibiotic susceptibility testing (AST) in approximately one hour.
Opportunities
Risk Factors
Competitive Landscape
Resistell competes in the rapid AST market against companies using molecular techniques (e.g., PCR, microarray) which detect resistance genes but may not always correlate with phenotypic expression, and other emerging phenotypic technologies. Its key differentiator is the combination of speed (~1 hour), phenotypic readout, and label-free detection. Competitors include established diagnostics firms and startups focusing on accelerating traditional culture methods or using microfluidics and imaging.